Eyepoint Investor Alert| MENAFN.COM

Saturday, 03 December 2022 09:28 GMT

Eyepoint Investor Alert


(MENAFN- Newsfile Corp) EyePoint Investor Alert Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options

New York, New York--(Newsfile Corp. - November 23, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ('Eyepoint' or the 'Company') (NASDAQ: EYPT).

If you suffered losses exceeding $50,000 investing in Eyepoint stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . You may also click here for additional information: .




There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

EyePoint Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company specializes in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. EyePoint Pharmaceuticals serves customers worldwide.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit

MENAFN23112022004218003983ID1105226010


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.